Rewinding RX review

Rewinding RX makes two commitments few sellers make. Every case is reviewed by a fully licensed MD matched to your state, stated flatly as never a physician assistant or nurse — although its own FAQ describes the network as including nurse practitioners, dermatologists and pharmacists. And its NAD⁺ listing publishes the concentration, the vial size, the total milligrams and a dosing ladder alongside the $139 subscription price, which is the only way a reader can actually work out what they are buying. Sermorelin is published at $189. The gap is the supply chain: the pharmacy is a 503A-compliant facility that is never named, and no medical director stands behind the network.

Rewinding RX Ltd. is a longevity-framed telehealth platform organized around anti-aging, skincare, supplements, weight management and its own "Rewind Systems" bundles. Its prescription line runs Rewind NAD⁺ and Rewind Sermorelin alongside compounded semaglutide and tirzepatide in standard, microdose and sublingual-drop forms, prescription skin creams, plus a tirzepatide-with-NAD⁺ combination and a supplement range including a proprietary NAD⁺-precursor formula. The company was founded by Mark E. Seremet, who is named on the site and tells his own story as the origin of the brand.

Asynchronous intake with a hard rule about who reads it: cases go to a fully licensed physician matched to the patient's state, and the site states outright that a physician assistant or nurse never makes the call, across a network it describes as 85-plus US physicians. In a category where mid-level review is the norm and rarely disclosed, making that commitment in public is meaningful — though the 85-plus figure is a claim with no browsable roster or credentials behind it, and the site's own FAQ muddies it by describing the clinician network as physicians, nurse practitioners, dermatologists and pharmacists. Ask who will review your case. Pricing is stated as flat and any-dose with no membership fee and no cancellation fee, free express shipping is included, the treatments page lists every product with its price, and the NAD⁺ page says you are charged only on medical approval. Disclosure is mixed. Positive: the operating entity Rewinding RX Ltd. is named, the site shows a LegitScript seal, all 50 states are claimed with physician state-licensing matching, the founder is named, and the site publishes the FDA compounded-medication disclaimer verbatim in its own footer — that the FDA does not review or approve any compounded medication for safety or effectiveness. Negative: the pharmacy is described only as a regulated US 503A-compliant facility and never named, no medical director or clinical leadership is identified, and no corporate address is published; the terms set Delaware law and send disputes to individual arbitration before the American Arbitration Association. The site also states that you may direct a prescription to an alternative pharmacy of your preference, which is a small but real piece of control.

Published on the treatments page for every product. Rewind NAD⁺ is $139 a month on subscription or $149 as a one-time purchase, described concretely as 1,000 mg in a 5 ml solution with every plan including a 30-day supply, online physician review, ongoing physician support, syringes, alcohol prep pads and free shipping. Rewind Sermorelin is $189, with pause or cancel at any time; its page does not spell out the supply period or inclusion list the way the NAD⁺ page does. Publishing 200 mg/ml, a 5 ml vial and a 1,000 mg total beside the price — plus a dosing ladder from 0.1 ml to 0.5 ml one to three times a week — is the level of specificity that makes cross-vendor comparison possible, and it is rare enough to be the reason to look. Note that the sermorelin listing does not carry the same concentration detail, so ask for it. On the weight-loss side, semaglutide is $139, tirzepatide $189, microdose semaglutide $119, microdose tirzepatide $169 and a tirzepatide-with-NAD⁺ combination $199, all flat by dose — those are GLP-1 numbers and are not peptide prices. Supplements are priced separately and are not prescription products.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Rewinding states in its own footer that physicians may prescribe compounded medications as needed and that the FDA does not review or approve compounded medications for safety or effectiveness — the correct disclosure, printed rather than buried, though the pharmacy is not named and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the two prescription longevity products are not comparable purchases. Sermorelin is a GHRH analog that stimulates the pituitary to release your own growth hormone rather than supplying it, preserving the somatostatin feedback loop that injected HGH overrides; the mechanism is real and well characterized, and the human outcome data thins out badly beyond short-term IGF-1 changes. Injected NAD⁺ has no controlled human outcome trials at all — the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly — and the NAD⁺ forms with human trial data are the oral precursors NR and NMN, which reliably raise blood NAD⁺: a raised biomarker rather than a demonstrated clinical benefit. That matters here in both directions, because Rewinding also sells an oral NAD⁺-precursor supplement stack; the supplement is the form with the human data, and the injection is the form with the marketing. Individual results vary.